EPOR Specific Neutra™ Antibody Products

Are you struggling with prolonged drug development timelines, inconsistent in vivo results, or challenges in targeting EPOR-mediated signaling networks? Creative Biolabs' EPOR specific Neutra™ antibody products leverage advanced hybridoma screening and epitope-specific engineering to deliver high-affinity, validated antibodies that streamline target validation, therapeutic candidate selection, and preclinical efficacy studies.

Introduction to EPOR

The erythropoietin receptor (EPOR), a member of the cytokine receptor superfamily, is primarily expressed on erythroid progenitor cells and mediates erythrocyte production. Upon binding its ligand erythropoietin (EPO), EPOR activates downstream signaling cascades critical for red blood cell differentiation and survival. Beyond erythropoiesis, EPOR is implicated in diverse cellular processes, including angiogenesis, tissue repair, and pathological conditions such as cancer progression.

• Structure

EPOR exists as a pre-dimerized homodimer stabilized by extracellular disulfide bonds. The receptor's extracellular domain contains two fibronectin type III subdomains responsible for EPO binding, while the transmembrane and intracellular domains facilitate signal transduction. Activation requires ligand-induced conformational changes that bring intracellular Janus kinase 2 (JAK2) binding domains into proximity, triggering autophosphorylation and downstream pathway activation. Structural studies reveal that pathogenic EPOR mutations disrupt autoinhibitory mechanisms, leading to constitutive signaling.

• Related Signaling Pathways

EPOR signaling is mediated through three major pathways:

- JAK2/STAT5: The primary pathway driving erythroid proliferation and differentiation. JAK2 phosphorylates STAT5, which translocates to the nucleus to activate target genes like Bcl-xL and GATA1.

- PI3K/AKT: Promotes cell survival by inhibiting apoptosis through Bad inactivation and mTOR activation.

- RAS/MAPK: Regulates erythroid progenitor expansion and stress erythropoiesis. Dysregulated EPOR signaling in malignancies often involves cross-talk with oncogenic pathways like HIF-1α.

Fig.1 EPOR-STAT5 signaling and its function.¹

• Related Diseases

Aberrant EPOR activation is central to polycythemia vera, myelodysplastic syndromes, and certain solid tumors. In cancer, autocrine EPO/EPOR signaling enhances tumor cell survival, angiogenesis, and resistance to chemotherapy. EPOR overexpression in breast, lung, and glioblastoma cancers correlates with aggressive phenotypes and poor prognosis. Additionally, chronic kidney disease-associated anemia is driven by impaired EPO production, underscoring EPOR's therapeutic relevance.

Applications of EPOR-Specific Neutralizing Antibodies

• Therapeutic Development for Hematologic Disorders

Anti-EPOR antibodies are advancing as biologics for polycythemia vera and myeloproliferative neoplasms. By competitively inhibiting EPO binding, these antibodies normalize erythrocyte counts and reduce thrombotic risks in preclinical models.

• Oncology: Disrupting Tumor Microenvironment Signaling

In EPOR-positive cancers, neutralizing antibodies inhibit pro-survival signals, sensitizing tumors to chemotherapy and radiation. Recent studies demonstrate reduced metastasis in breast cancer xenografts treated with anti-EPOR antibodies.

• Research Tools for Mechanistic Studies

Anti-EPOR antibodies enable precise interrogation of receptor dimerization dynamics, downstream phosphorylation events, and cross-talk with oncogenic pathways. Applications include flow cytometry, phospho-STAT5 assays, and co-culture systems modeling bone marrow niches.

Our Anti-EPOR Neutralizing Antibodies

EPOR-specific neutralizing antibodies inhibit pathological signaling by blocking ligand-receptor interactions or preventing receptor dimerization. Key applications include:

• Inhibiting Erythrocytosis: Neutralizing antibodies suppress hyperactive EPOR signaling in polycythemia vera.
• Anticancer Therapies: Antibodies targeting tumor-associated EPOR disrupt survival pathways and chemoresistance.
• Preclinical Research: Tools for studying EPOR's role in erythropoiesis and tumor microenvironment interactions.

Creative Biolabs' antibodies exhibit >90% neutralization efficiency, cross-reactivity with primate EPOR orthologs, and low lot-to-lot variability, ensuring reproducibility in translational research

Creative Biolabs' EPOR specific Neutra™ antibody products empower researchers and therapeutic developers with rigorously validated tools to overcome EPOR-related challenges. Our antibodies are optimized for functional assays, in vivo models, and high-throughput screening. Contact our team today to discuss your EPOR-focused project and explore customized solutions.

REFERENCE

1. Tóthová, Zuzana, et al. "STAT5 as a key protein of erythropoietin signalization." International journal of molecular sciences 22.13 (2021): 7109. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms22137109